AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05403554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological NI-1801
Description: Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
Study NCT04936334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET Scan
Description: Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
Study NCT06540352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
Description: The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
Study NCT06540352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Placebo in tablets
Study NCT05403554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-1801 in combination with anti-PD1 (Pembrolizumab)
Description: In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
Study NCT05403554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NI-1801 in combination with paclitaxel
Description: The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
Study NCT05403554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
Study NCT06179082 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Botox then threads
Description: patients in which Botox injection then threads insertion were used
Study NCT06179082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: threads only
Description: patients in which threads insertion only was used
Study NCT04389411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Description: 10mg oral Montelukast will be taken daily for 60 days
Study NCT04389411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10mg
Description: 10mg oral Montelukast will be taken daily for 60 days
Study NCT05176093 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engensis
Description: Lyophilized biologic to be reconstituted containing Engensis
Study NCT05176093 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable Liquid
Study NCT05543785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
Study NCT05543785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
Study NCT05624099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: 200mg intravenous drip d1q3w
Study NCT05624099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel drugs
Description: 150mg/m2 d1 q3w
Study NCT05624099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum drug
Description: Cisplatin, carboplatin, nedaplatin and other platinum drugs
Study NCT05624099 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Dose: 5040cGy/28f
Study NCT05771272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sit and Reach Test
Description: To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
Study NCT05771272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Weight Bearing Lunge Test
Description: To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
Study NCT06196892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic BBr60
Description: Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.
Study NCT06196892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic BBr60
Description: Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.
Study NCT05204667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily
Description: (2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
Study NCT05204667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily
Description: (2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
Study NCT04945226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride 1mg Tablet
Description: Propecia Tablet 1mg
Study NCT04945226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3001
Description: Finasteride long acting injection
Study NCT05844995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium
Description: Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
Study NCT04843891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64]Cu Macrin
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
Study NCT04965597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV
Study NCT04965597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04965597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT04965597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT04965597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo bone marrow transplant
Study NCT06399328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Surface Enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
Study NCT05371535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MatrixOssTM Bone Graft plus Bio-Gide membrane
Description: To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
Study NCT05371535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatrixOssTM Bone Graft plus Bio-Gide membrane
Description: To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
Study NCT05314946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No feeding tube placed
Description: The experimental arm will forego placement of a feeding tube.
Study NCT05314946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a percutaneous feeding tube
Description: The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
Study NCT05493995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200 mg administered intravenously every 3 weeks.
Study NCT05493995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
Study NCT05493995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
Study NCT05493995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
Study NCT05770466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b)
Description: 1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines
Study NCT05770466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
Study NCT05770466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
Study NCT05800327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levilimab
Description: Subcutaneous or intravenous injection of levilimab with placebo.
Study NCT06184334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solfenacin
Description: pills taken once day
Study NCT06184334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: pills taken once day
Study NCT06184334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: pills taken once day
Study NCT06501131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: full-spectrum light exposure
Description: Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
Study NCT06501131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific spectrum absence light exposure
Description: Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
Study NCT05270772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T-19 Cells
Description: T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
Study NCT04725214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib With STUPP Regimen
Study NCT05012605 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observe physical function and sleep disorder symptoms following stroke
Study NCT06354153 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polarity Management Training Program
Description: 60 first-line nurse managers received a training program involving theoretical and practical sessions
Study NCT05180994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical infliximab
Description: Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
Study NCT05180994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No topical infliximab
Description: No treatment with infliximab.
Study NCT06573021 — intervention group
Intervention type: DRUG
Intervention: Near-infrared fluorescent cholangiography
Description: For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
Study NCT06573190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography
Description: Liver Stiffness Measurement, Controlled Attenuation Parameter
Study NCT06573190 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: Guided Therapy
Study NCT06572839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnio-Maxx
Description: Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
Study NCT06333626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-vitamin carbohydrate
Description: oral multi-vitamin carbohydrate beverage
Study NCT05790434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory test
Description: including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
Study NCT05790434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: History taking and physical examination
Description: including fever, joint pain, local swelling and redness, sinus
Study NCT05159726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education
Description: 12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
Study NCT06159699 — intervention group
Intervention type: OTHER
Intervention: Online Survey
Description: The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
Study NCT06159699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
Study NCT05790434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: including arthrocentesis culture，and frozen section
Study NCT04694196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentulous subjects
Description: Determine the occlusal plane using CN in anterior border of ramus
Study NCT06663397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
Study NCT06663397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Childbirth Preparation Training
Description: the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
Study NCT06663397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Childbirth Preparation Training
Description: the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
Study NCT06662552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration using crazy fit machine
Description: It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient
Study NCT06662552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic field therapy
Description: EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient
Study NCT06662552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
Study NCT06662552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
Study NCT06663865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: 40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment
Study NCT06663865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment
Study NCT05825482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.
Description: Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.